Aflibercept for Diabetic Macular Edema: Long-Term Vision Benefits
Aflibercept 8 mg demonstrates Sustained Efficacy and Durability in Diabetic Macular Edema Through 156 Weeks
Table of Contents
Extended Dosing Intervals Achieved in PHOTON Extension Study, Supporting Longer Duration of Action
Long Beach, CA - New findings from teh PHOTON extension study, presented at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists, highlight the sustained efficacy and durability of aflibercept 8 mg in patients with diabetic macular edema (DME). The study evaluated long-term treatment outcomes up to 156 weeks,demonstrating that aflibercept 8 mg can maintain visual and anatomical improvements while allowing for extended dosing intervals in a significant proportion of patients.
Key Findings from the PHOTON Extension Study
The PHOTON extension study built upon the initial two-year results of the pivotal PHOTON trial, which investigated aflibercept 8 mg for DME. After the initial 96 weeks, patients who had been randomized to either 8q12 or 8q16 aflibercept 8 mg continued receiving the same treatment. Those who were initially on a 2q8 aflibercept regimen were switched to aflibercept 8 mg with 12-week dosing intervals.
From week 100 onwards, investigators had the flexibility to adjust dosing intervals, either shortening or extending them, provided specific criteria were met. This approach allowed for a personalized treatment strategy based on individual patient responses.
at the 156-week mark, both the group that continued on aflibercept 8 mg (8mg group) and the group that switched to aflibercept 8 mg with 12-week intervals (2q8-8mg group) showed maintained visual and anatomical improvements. Notably, the 2q8-8mg group exhibited a considerably slower rate of fluid reaccumulation eight weeks after their first aflibercept 8 mg injection compared to the rate observed eight weeks after aflibercept 2 mg injections during the first two years of the study. This finding strongly suggests a longer duration of action for aflibercept 8 mg.
Extended Dosing Intervals and Safety Profile
The study also provided compelling evidence for the achievability of extended dosing intervals with aflibercept 8 mg. Among the patients in the 8mg group who completed the extension, a significant 45% had a last completed dosing interval of 20 weeks or longer, and 48% had a last assigned dosing interval of 20 weeks or longer.
For the 2q8-8mg group, a remarkable 83% of patients had a last assigned dosing interval of 12 weeks or longer through week 156. These results underscore the potential for less frequent injections,which can significantly improve patient convenience and adherence.
Crucially, the investigators reported no new safety signals throughout the duration of the extension study. This reinforces the favorable safety profile of aflibercept 8 mg, even with extended treatment durations and intervals.
Expert Commentary
“The achievement of extended dosing intervals with aflibercept 8 mg in the vast majority of patients, together with the slower fluid reaccumulation observed following a switch from aflibercept 2 mg to 8 mg, supports the longer duration of action of aflibercept 8 mg versus 2 mg,” stated Schneider and colleagues in their findings.This sentiment highlights the clinical significance of these results for managing DME.
The sustained efficacy, durability, and favorable safety profile, coupled with the potential for extended dosing intervals, position aflibercept 8 mg as a valuable long-term treatment option for individuals living with diabetic macular edema.
References:*
- Schneider E. Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results from the PHOTON Extension Study. abstract presented at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists in Long Beach, CA, July 30-august 2, 2025.
- Two-year Results for Aflibercept 8 mg from Pivotal PHOTON Trial Demonstrate Durable Vision Gains at Extended Dosing Intervals in diabetic Macular Edema. Regeneron. June 27, 2023. Accessed July 31, 2025.[https://investorregeneroncom/news-releases/news-release-details/two-year-[https://investorregeneroncom/news-releases/news-release-details/two-year-[https://investorregeneroncom/news-releases/news-release-details/two-year-[https://investorregeneroncom/news-releases/news-release-details/two-year-